Exposure to bisphosphonates and risk of cancer: A protocol for nested case - Control studies using the QResearch primary care database

BMJ Open

Volumn 2, Issue 1, 2012, Pages

  Vinogradova, Yana ^a   Coupland, Carol ^a   Hippisley Cox, Julia ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETIDRONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DATA BASE; DRUG EXPOSURE; DRUG UTILIZATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HORMONE SUBSTITUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; OSTEOPOROSIS; OVARY CANCER; PANCREAS CANCER; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY TUMOR; PROSTATE CANCER; RISK ASSESSMENT; SMOKING; SOCIAL STATUS; STOMACH CANCER; TREATMENT DURATION; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 84857871071     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000548     Document Type: Article

References (54)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33. (Pubitemid 44607392)
2. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63:843-9. (Pubitemid 47237896)
3. Joint Formulary Committee. British National Formulary London. British Medical Association and Royal Pharmaceutical Society of Great Britain. 62 ed. London: BMJ Group and Pharmaceutical Press; 2011.
4. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, strontium ranelate and raloxifen for preventing bone fractures in postmenopausal women with osteoporosis who have not had a fracture. information about NICE technology appraisal guidance. London: National Institute for Health and Clinical Excellence, 2008;160.
5. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, strontium ranelate and teriparatide for preventing bone fractures in postmenopausal women with osteoporosis who have already had a fracture. Information about NICE technology appraisal guidance. 2008;161.
6. Kanis J, McCloskey E, Johansson H, et al. Case finding for the management of osteoporosis with FRAX-dassessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408.
7. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
8. Watts NB, Diab DL. Long-Term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65.
9. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008;34(Suppl 1):S19-24.
10. Croucher P, Jagdev S, Coleman R. The anti-tumor potential of zoledronic acid. Breast 2003;12(Suppl 2):S30-6. (Pubitemid 40023561)
11. Santini D, Fratto ME, Galluzzo S, et al. Are bisphosphonates the suitable anticancer drugs for the elderly? Crit Rev Oncol Hematol 2009;69:83-94.
12. Gnant M. Can oral bisphosphonates really reduce the risk of breast cancer in Healthy women? J Clin Oncol 2010;28:3548-51.
13. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28:3582-90.
14. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102:799-802.
15. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28:3577-81.
16. Vestergaard P, Fischer L, Mele M, et al. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int 2011;88:255-62.
17. Fortuny J, Sima C, Bayuga S, et al. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 2009;18:1448-56.
18. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
19. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med 2009;360:1789.
20. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:c4444.
21. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
22. Rennert G, Pinchev M, Rennert HS, et al. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011;29:1146-50.
23. Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011;89:434-41.
24. Mellström DD, Sörensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8. (Pubitemid 40174503)
25. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 Years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. (Pubitemid 46021497)
26. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. (Pubitemid 38339363)
27. Pfizer. Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU). 2011. B1781044. http://www.clinicaltrials.gov
28. Hammersley V, Hippisley-Cox J, Wilson A, et al. A comparison of research general practices and their patients with other practicesdcross sectional survey in Trent. Br J Gen Pract 2002;52:463-8. (Pubitemid 34578183)
29. Hippisley-Cox J, Hammersley V, Pringle M, et al. How useful are General Practice databases for research? Analysis of their accuracy and completeness in one research network. Health Inform J 2004;10:91-109.
30. Westlake S. Cancer incidence and mortality in the United Kingdom and constituent countries, 2004-06. Health Stat Q. 2009 Autumn; 43:56-62.
31. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61. (Pubitemid 40911458)
32. Henderson KD, Bernstein L. Etiology of Cancer: Obesity and Physical Activity. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2008:239-44.
33. Hecht SS. Etiology of Cancer: Tobacco. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. Wolters Kluwer/ Lippincott Williams & Wilkins, Philadelphia, 2008:147-55.
34. Schütze M, Boeing H, Pischon T, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011;342:d1584.
35. Forman D. Cancer Incidence by Deprivation. England, 1995-2004. 2008. http://wwwncinorguk/publications/reports/defaultaspx, http://www.ncin.org.uk/ publications/reports/default.aspx
36. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
37. McGlynn KA, Gridley G, Mellemkjaer L, et al. Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer 2008;122:1879-84. (Pubitemid 351413438)
38. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of Hip fracture. JAMA 2006;296:2947-53. (Pubitemid 46021498)
39. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
40. González-Pérez A, Garcia Rodriguez L, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003;3:28.
41. Mocellin S. Vitamin D and cancer: deciphering the truth. Biochim Biophys Acta 2011;1816:172-8.
42. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
43. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011;12:65-82.
44. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378:607-20.
45. Burbos N, Musonda P, Giarenis I, et al. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer 2010;102:1201-6.
46. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-7. (Pubitemid 46354334)
47. Rustgi AK. Cancers of the Gastrointestinal Tract. DeVita, Hellman, and Rosenberg's cancer: Principles & Practice of Oncology. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 2008:989-1313.
48. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-93.
49. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37. (Pubitemid 41058322)
50. Mai PL, Garceau AO, Graubard BI, et al. Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 2011;103:788-97.
51. Chang ET, Smedby KE, Hjalgrim H, et al. Reliability of self-reported family history of cancer in a large caseecontrol study of lymphoma. J Natl Cancer Inst 2006;98:61-8. (Pubitemid 43057093)
52. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45. (Pubitemid 351347060)
53. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
54. García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006;55:1538-44. (Pubitemid 44629198)